Politics / Law

EMA under fire from MEPs

10.06.2011

London – In mid-May, the European Medicines Agency was under pressure from the European Parliament, which postponed signing off on its accounts for the financial year 2009. The decision came on the heels of a critical report from the EU’s Budgetary Control Committee complaining that there was no guarantee ensuring the independence of experts hired to carry out scientific evaluations of human medicines at the agency. More eyebrows were raised when – just two weeks after he left the EMA – former chief Thomas Lönngren took a position as a strategic consultant with the UK-based NDA Group that advises pharmaceutical companies on developing new medications and reducing the length of time to market introduction. Lönngren also joined the board of the Australian drug developer CBio, and took on a post as a strategic advisor to VC specialist Essex Woodlands. In March, the EMA then stated that Lönngren will have to wait at least two years before taking other positions in the pharmaceutical industry. However, the conflict-of-interest policy seems to have loopholes in not defining exactly what kinds of post-EMA activities in the pharma sector or industry associations are acceptable. The agency has now been asked by the European Parliament to provide a report by June 30th listing all “comparable cases” of (ex)staff associations with pharma companies that have occurred since the creation of the agency, explaining in detail the management board’s decision in each case.
The move came at the right time to draw attention from the revelation that some MEPs might sell their votes. A recent operation showed that some MEPs were willing to sell votes to British journalists pretending to be lobbyists who asked them what a vote would cost. In May, the European Parliament greenlighted the establishment of a transparency register aimed at monitoring any payments from lobbyists to MEPs or European Commission staff. Although a step forward, the move is not legally binding.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/ema-under-fire-from-meps.html

Events

All Events

Stock list

All quotes

TOP

  • BIOFRONTERA2.44 EUR10.91%
  • WILEX2.19 EUR4.29%
  • PAION3.28 EUR1.86%

FLOP

  • SANTHERA83.00 CHF-4.54%
  • EVOLVA1.19 CHF-4.03%
  • BB BIOTECH149.65 EUR-2.95%

TOP

  • PAION3.28 EUR36.1%
  • CO.DON3.05 EUR24.0%
  • FORMYCON8.17 EUR15.9%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.05 EUR-18.0%
  • 4SC1.01 EUR-14.4%

TOP

  • SANTHERA83.00 CHF2044.7%
  • PAION3.28 EUR245.3%
  • CO.DON3.05 EUR214.4%

FLOP

  • CYTOS0.18 CHF-95.3%
  • 4SC1.01 EUR-46.0%
  • MOLOGEN6.64 EUR-44.2%

No liability assumed, Date: 01.10.2014


Current issue

All issues

Product of the week

Products